RecruitingNCT06694779

Thrombosis in Diffuse Large B-cell Lymphoma:the PREDIC-TO (PREDICt ThrOmbosis) Study

Thrombosis in Diffuse Large B-cell Lymphoma: Impact on Outcome, Evaluation, and Comparison of Predictive Models of Thrombotic Risk: Multicentre Retrospective Observational Study. the PREDIC-TO (PREDICt ThrOmbosis) Study


Sponsor

Fondazione IRCCS San Gerardo dei Tintori

Enrollment

1,000 participants

Start Date

May 25, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

Comparative Evaluation of Thrombotic Risk Models in DLBCL patients Objective: To assess the impact of thrombotic risk factors and compare the performance of existing predictive models (Khorana, Throly, Model IX) in Diffuse Large B-cell Lymphoma (DLBCL) Primary Endpoints: Measure thrombotic risk factors in existing models Determine occurrence, type, and timing of venous thrombotic events Secondary Endpoints: Assess performance of models in patients without thrombotic events at diagnosis Evaluate dynamic risk factors during DLBCL treatment Identify additional risk factors not included in published models Analyze overall survival and VTE-free survival Methodology: Real-world cohort study of DLBCL patients Collection of static and dynamic risk factors Correlation analysis of risk factors with thrombotic events Development and validation of DLBCL-specific predictive model Conclusion: This study aims to compare existing predictive models and develop a DLBCL-specific model to aid in identifying high-risk patients and inform thromboprophylaxis decisions. Results will contribute to improved understanding and management of thrombotic risk in DLBCL.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This observational study is tracking blood clotting complications (thrombosis) in patients newly diagnosed with diffuse large B-cell lymphoma (DLBCL) — a common and aggressive blood cancer — to develop better tools to predict who is at risk of developing dangerous blood clots during treatment. **You may be eligible if...** - You are 18 or older - You have been newly diagnosed with DLBCL, confirmed by a tissue biopsy - You are willing to provide informed consent **You may NOT be eligible if...** - You are already taking anticoagulant (blood-thinning) medications at the time of your diagnosis - You started preventive blood thinners (heparin) immediately after your DLBCL diagnosis - Not enough information is available to calculate blood clot risk scores at the time of diagnosis Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Ivan Civettini

Monza, Italy, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06694779


Related Trials